Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

INTRODUCTION: Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical models and two prior studies demonstrated promising activity in patients with breast cancer. We conducted a study of extended rele...

Descripción completa

Detalles Bibliográficos
Autores principales: Cottu, Paul H., Bonneterre, Jacques, Varga, Andrea, Campone, Mario, Leary, Alexandra, Floquet, Anne, Berton-Rigaud, Dominique, Sablin, Marie-Paule, Lesoin, Anne, Rezai, Keyvan, Lokiec, François M., Lhomme, Catherine, Bosq, Jacques, Bexon, Alice S., Gilles, Erard M., Proniuk, Stefan, Dieras, Veronique, Jackson, David M., Zukiwski, Alexander, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179222/
https://www.ncbi.nlm.nih.gov/pubmed/30304013
http://dx.doi.org/10.1371/journal.pone.0204973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179222/
https://www.ncbi.nlm.nih.gov/pubmed/30304013
http://dx.doi.org/10.1371/journal.pone.0204973

Ejemplares similares